Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

Research could lead to more efficient cellular immunotherapies for advanced cancers

Adoptive cell transfer immunotherapy is one of the most promising new treatments for people with hard-to-treat cancers.

23 Jul 2020

Seroprevalence of SARS-CoV-2 antibody among blood donors in China

Now, a study published on the preprint server medRxiv* in July 2020 reports on the low seroprevalence of antibodies to the virus, now designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), among blood donors in Wuhan, the Chinese city it all started in, and two other equally large cities in China.

17 Jul 2020

New insight into the SARS-CoV-2 infection process

Canadian researchers from the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, have found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be using a unique method to gain entry into the cells.

16 Jul 2020

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

By performing a genome-wide CRISPR screen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), U.S. researchers identified novel proviral genes and pathways, and highlighted host genes that may regulate coronavirus disease (COVID-19) pathogenesis, as well as revealing potential targets for novel treatment approaches. Their findings are currently available on the bioRxiv* preprint server.

18 Jun 2020

SARS-CoV-2 mutated spike proteins show variations in cell entry

A new study by Japanese scientists published on the preprint server bioRxiv* in June 2020 shows that the D614g mutation in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein can enhance the infectivity of the virus while leaving it vulnerable to neutralization by antibodies.

17 Jun 2020

Gyros Protein Technologies launches Gyrolab p24 Kit for scientists in cell and gene therapy market

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® p24 Kit, for lentivirus titer determination in lentivirus vector manufacturing.

From Gyros Protein Technologies AB 11 Sep 2019

New gene therapy cures babies with fatal 'Bubble Boy' disease

A new gene therapy created by US researchers appears to have cured eight infant boys born with a rare genetic disorder referred to as “Bubble Boy” disease.

18 Apr 2019

Researchers develop new strategy to treat sickle cell disease and beta thalassemia

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases -- sickle cell disease and beta thalassemia -- applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

29 Mar 2019

New gene therapy treatment for Sickle Cell Anemia reverses symptoms in adults

After over a decade of preclinical research and development, a new gene therapy treatment for Sickle Cell Anemia is reversing disease symptoms in two adults and showing early potential for transportability to resource-challenged parts of the world where SCA is most common.

3 Dec 2018

New method increases virus production in cells to generate more vectors for gene transfer

Researchers at Tokyo Medical and Dental University have established a method to increase the released lentiviral particles produced by host cells, which will aid the use of the vectors for introducing foreign genes into cells

29 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Novel lentiviral model can determine effect of Wnt/β-Catenin inhibition on bone regeneration

Researchers have developed a novel tool for determining the sensitivity of bone healing to inhibition of the Wnt signaling pathway and have validated its use in a study of bone regeneration in mice.

4 Sep 2018

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

The California Institute for Regenerative Medicine board has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy.

30 Jun 2018

Mapping the Genes Responsible for Pluripotency

Dr. Atilgan Yilmaz and his team have developed a method by which they can produce haploid human embryonic stem cells from oocytes. They combined this technique with CRISPR-Cas9 to generate an atlas of the genome, containing the functions of over 18,000 genes.

23 May 2018

Lentivirus News and Research

Further Reading

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

Research could lead to more efficient cellular immunotherapies for advanced cancers

Seroprevalence of SARS-CoV-2 antibody among blood donors in China

New insight into the SARS-CoV-2 infection process

Moderna vaccine induces robust immune response against SARS-CoV-2

First genome-wide CRISPR screen reveals genes that control SARS-CoV-2 infection

SARS-CoV-2 mutated spike proteins show variations in cell entry

Gyros Protein Technologies launches Gyrolab p24 Kit for scientists in cell and gene therapy market

New gene therapy cures babies with fatal 'Bubble Boy' disease

Researchers develop new strategy to treat sickle cell disease and beta thalassemia

New gene therapy treatment for Sickle Cell Anemia reverses symptoms in adults

New method increases virus production in cells to generate more vectors for gene transfer

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Novel lentiviral model can determine effect of Wnt/β-Catenin inhibition on bone regeneration

City of Hope receives $3.7 million from CIRM to develop phase 1 glioblastoma trial

Mapping the Genes Responsible for Pluripotency

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News